Main Menu

Dr Dragomir Krastev

Senior Researcher

The alt text
Dr Dragomir Krastev is a postdoctoral fellow who specialises in studying the mechanisms and regulation of a type of post-translational protein modification called PARsylation. Team: Gene Function

T 020 7153 5332

Biography and research overview

Dr Krastev is working on an independent research project to develop novel methods for studying poly(ADP-ribose)ylation, or PARsylation, in vivo, employing a set of genetic and functional assays to interrogate this process on a molecular level. He works alongside Prof Alan Ashworth’s Gene Function Team, with access to the laboratory’s expertise in cutting-edge next-generation sequencing, functional genomics and pharmacology.

Dr Krastev’s research develops and establishes the applications of in vivo biosensors to study a process of interest – PARsylation. These sensors produce a fluorescent signal only when a protein of interest is PARsylated. This allows him to ask such questions as which factors regulate the amount of PARsylation of a specific target protein or pathway, and to study how PARsylation can be modulated by genetic or pharmacological means. In addition, combining PAR biosensors with transposon-mediated genome modification provides a strategy to identify in an unbiased manner new PARsylation targets. This approach has significant advantages over previously employed in vitro purification techniques and is bound to produce a wealth of novel targets. The Gene Function team, with its expertise in transposon genomics, provides an ideal environment for the project.

PARsylation is a very promising target in anti-cancer therapy and a number of drugs that target it in vivo are being developed. However, how exactly these drugs affect the multifaceted PAR-mediated regulation of cancer cells remains largely unexplored. The pathway-specific biosensors that Dr Krastev is developing will allow scientists to dissect the precise mechanisms of PAR regulation. This will clarify which targets are relevant in anti-cancer research and will inform the rational design of drug combinations with PARsylation inhibitors.

We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.